APO Research
Talk to an analyst

APO RESEARCH · REPORT

IL-17 Monoclonal Antibody Injections

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global IL-17 Monoclonal Antibody Injections Market Outlook and Growth Opportunities 2026

29 December 2025196 pages

Choose your research edition.

Industry ResearchIL-17 Monoclonal Antibody Injections Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal IL-17 Monoclonal Antibody Injections Industry Growth and Trends Forecast to 203271 pages · $3,450 USDMarket StructureGlobal IL-17 Monoclonal Antibody Injections Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IL-17 Monoclonal Antibody Injections Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal IL-17 Monoclonal Antibody Injections Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global IL-17 Monoclonal Antibody Injections market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for IL-17 Monoclonal Antibody Injections is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for IL-17 Monoclonal Antibody Injections is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IL-17 Monoclonal Antibody Injections is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the IL-17 Monoclonal Antibody Injections market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the IL-17 Monoclonal Antibody Injections market include Novartis, Eli Lilly and Co., UCB and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global IL-17 Monoclonal Antibody Injections market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of IL-17 Monoclonal Antibody Injections and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents IL-17 Monoclonal Antibody Injections sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the IL-17 Monoclonal Antibody Injections market size, projected growth trends, production technologies, key applications, and end-use industries.

IL-17 Monoclonal Antibody Injections Segment by Company

Novartis

Eli Lilly and Co.

UCB

AstraZeneca

IL-17 Monoclonal Antibody Injections Segment by Type

Human Origin

Rat Origin

Other

IL-17 Monoclonal Antibody Injections Segment by Application

Hospital

Clinic

Other

IL-17 Monoclonal Antibody Injections Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global IL-17 Monoclonal Antibody Injections status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions IL-17 Monoclonal Antibody Injections market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify IL-17 Monoclonal Antibody Injections significant trends, drivers, influence factors in global and regions.

6. To analyze IL-17 Monoclonal Antibody Injections competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-17 Monoclonal Antibody Injections market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IL-17 Monoclonal Antibody Injections and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-17 Monoclonal Antibody Injections.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the IL-17 Monoclonal Antibody Injections market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global IL-17 Monoclonal Antibody Injections industry.

Chapter 3: Detailed analysis of IL-17 Monoclonal Antibody Injections manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of IL-17 Monoclonal Antibody Injections in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of IL-17 Monoclonal Antibody Injections in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. IL-17 Monoclonal Antibody Injections Industry Trends Table 2. IL-17 Monoclonal Antibody Injections Industry Drivers Table 3. IL-17 Monoclonal Antibody Injections Industry Opportunities and Challenges Table 4. IL-17 Monoclonal Antibody Injections Industry Restraints Table 5. Global IL-17 Monoclonal Antibody Injections Revenue by Company (US$ Million) & (2021-2026) Table 6. Global IL-17 Monoclonal Antibody Injections Revenue Share by Company (2021-2026) Table 7. Global IL-17 Monoclonal Antibody Injections Sales Volume by Company (K Units) & (2021-2026) Table 8. Global IL-17 Monoclonal Antibody Injections Sales Volume Share by Company (2021-2026) Table 9. Global IL-17 Monoclonal Antibody Injections Average Price (US$/Unit) of Company (2021-2026) Table 10. Global IL-17 Monoclonal Antibody Injections Company Ranking, (2024-2026) & (USD Million) Table 11. Global IL-17 Monoclonal Antibody Injections Key Company Manufacturing Base & Headquarters Table 12. Global IL-17 Monoclonal Antibody Injections Company, Product Type & Application Table 13. Global IL-17 Monoclonal Antibody Injections Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global IL-17 Monoclonal Antibody Injections by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Human Origin Table 18. Significant Companies of Rat Origin Table 19. Significant Companies of Other Table 20. Global IL-17 Monoclonal Antibody Injections Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global IL-17 Monoclonal Antibody Injections Sales Volume by Type (2021-2026) & (K Units) Table 22. Global IL-17 Monoclonal Antibody Injections Sales Volume by Type (2027-2032) & (K Units) Table 23. Global IL-17 Monoclonal Antibody Injections Sales Volume Share by Type (2021-2026) Table 24. Global IL-17 Monoclonal Antibody Injections Sales Volume Share by Type (2027-2032) Table 25. Global IL-17 Monoclonal Antibody Injections Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global IL-17 Monoclonal Antibody Injections Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global IL-17 Monoclonal Antibody Injections Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global IL-17 Monoclonal Antibody Injections Sales Value Share by Type (2021-2026) Table 29. Global IL-17 Monoclonal Antibody Injections Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Clinic Table 32. Significant Companies of Other Table 33. Global IL-17 Monoclonal Antibody Injections Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global IL-17 Monoclonal Antibody Injections Sales Volume by Application (2021-2026) & (K Units) Table 35. Global IL-17 Monoclonal Antibody Injections Sales Volume by Application (2027-2032) & (K Units) Table 36. Global IL-17 Monoclonal Antibody Injections Sales Volume Share by Application (2021-2026) Table 37. Global IL-17 Monoclonal Antibody Injections Sales Volume Share by Application (2027-2032) Table 38. Global IL-17 Monoclonal Antibody Injections Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global IL-17 Monoclonal Antibody Injections Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global IL-17 Monoclonal Antibody Injections Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global IL-17 Monoclonal Antibody Injections Sales Value Share by Application (2021-2026) Table 42. Global IL-17 Monoclonal Antibody Injections Sales Value Share by Application (2027-2032) Table 43. Global IL-17 Monoclonal Antibody Injections Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global IL-17 Monoclonal Antibody Injections Sales by Region (2021-2026) & (K Units) Table 45. Global IL-17 Monoclonal Antibody Injections Sales Market Share by Region (2021-2026) Table 46. Global IL-17 Monoclonal Antibody Injections Sales by Region (2027-2032) & (K Units) Table 47. Global IL-17 Monoclonal Antibody Injections Sales Market Share by Region (2027-2032) Table 48. Global IL-17 Monoclonal Antibody Injections Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global IL-17 Monoclonal Antibody Injections Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global IL-17 Monoclonal Antibody Injections Sales Value Share by Region (2021-2026) Table 51. Global IL-17 Monoclonal Antibody Injections Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global IL-17 Monoclonal Antibody Injections Sales Value Share by Region (2027-2032) Table 53. Global IL-17 Monoclonal Antibody Injections Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global IL-17 Monoclonal Antibody Injections Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global IL-17 Monoclonal Antibody Injections Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global IL-17 Monoclonal Antibody Injections Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global IL-17 Monoclonal Antibody Injections Sales by Country (2021-2026) & (K Units) Table 58. Global IL-17 Monoclonal Antibody Injections Sales Market Share by Country (2021-2026) Table 59. Global IL-17 Monoclonal Antibody Injections Sales by Country (2027-2032) & (K Units) Table 60. Global IL-17 Monoclonal Antibody Injections Sales Market Share by Country (2027-2032) Table 61. Global IL-17 Monoclonal Antibody Injections Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global IL-17 Monoclonal Antibody Injections Sales Value Market Share by Country (2021-2026) Table 63. Global IL-17 Monoclonal Antibody Injections Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global IL-17 Monoclonal Antibody Injections Sales Value Market Share by Country (2027-2032) Table 65. Novartis Company Information Table 66. Novartis Business Overview Table 67. Novartis IL-17 Monoclonal Antibody Injections Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Novartis IL-17 Monoclonal Antibody Injections Product Portfolio Table 69. Novartis Recent Development Table 70. Eli Lilly and Co. Company Information Table 71. Eli Lilly and Co. Business Overview Table 72. Eli Lilly and Co. IL-17 Monoclonal Antibody Injections Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Eli Lilly and Co. IL-17 Monoclonal Antibody Injections Product Portfolio Table 74. Eli Lilly and Co. Recent Development Table 75. UCB Company Information Table 76. UCB Business Overview Table 77. UCB IL-17 Monoclonal Antibody Injections Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. UCB IL-17 Monoclonal Antibody Injections Product Portfolio Table 79. UCB Recent Development Table 80. AstraZeneca Company Information Table 81. AstraZeneca Business Overview Table 82. AstraZeneca IL-17 Monoclonal Antibody Injections Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. AstraZeneca IL-17 Monoclonal Antibody Injections Product Portfolio Table 84. AstraZeneca Recent Development Table 85. Key Raw Materials Table 86. Raw Materials Key Suppliers Table 87. IL-17 Monoclonal Antibody Injections Distributors List Table 88. IL-17 Monoclonal Antibody Injections Customers List Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. IL-17 Monoclonal Antibody Injections Product Image Figure 2. Global IL-17 Monoclonal Antibody Injections Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IL-17 Monoclonal Antibody Injections Sales Value (2021-2032) & (US$ Million) Figure 4. Global IL-17 Monoclonal Antibody Injections Sales (2021-2032) & (K Units) Figure 5. Global IL-17 Monoclonal Antibody Injections Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global IL-17 Monoclonal Antibody Injections Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Human Origin Image Figure 10. Rat Origin Image Figure 11. Other Image Figure 12. Global IL-17 Monoclonal Antibody Injections Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global IL-17 Monoclonal Antibody Injections Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global IL-17 Monoclonal Antibody Injections Sales Volume Share by Type (2021-2032) Figure 15. Global IL-17 Monoclonal Antibody Injections Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global IL-17 Monoclonal Antibody Injections Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global IL-17 Monoclonal Antibody Injections Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Other Image Figure 21. Global IL-17 Monoclonal Antibody Injections Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global IL-17 Monoclonal Antibody Injections Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global IL-17 Monoclonal Antibody Injections Sales Volume Share by Application (2021-2032) Figure 24. Global IL-17 Monoclonal Antibody Injections Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global IL-17 Monoclonal Antibody Injections Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global IL-17 Monoclonal Antibody Injections Sales Value Share by Application (2021-2032) Figure 27. Global IL-17 Monoclonal Antibody Injections Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global IL-17 Monoclonal Antibody Injections Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global IL-17 Monoclonal Antibody Injections Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global IL-17 Monoclonal Antibody Injections Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America IL-17 Monoclonal Antibody Injections Sales Value (2021-2032) & (US$ Million) Figure 32. North America IL-17 Monoclonal Antibody Injections Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe IL-17 Monoclonal Antibody Injections Sales Value (2021-2032) & (US$ Million) Figure 34. Europe IL-17 Monoclonal Antibody Injections Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific IL-17 Monoclonal Antibody Injections Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific IL-17 Monoclonal Antibody Injections Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America IL-17 Monoclonal Antibody Injections Sales Value (2021-2032) & (US$ Million) Figure 38. South America IL-17 Monoclonal Antibody Injections Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa IL-17 Monoclonal Antibody Injections Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa IL-17 Monoclonal Antibody Injections Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. IL-17 Monoclonal Antibody Injections Value Chain Figure 126. Manufacturing Cost Structure Figure 127. IL-17 Monoclonal Antibody Injections Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Human Origin
  • Rat Origin
  • Other
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Novartis
  • Eli Lilly and Co.
  • UCB
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global IL-17 Monoclonal Antibody Injections Sales Value (2021-2032)
  4. 1.2.2 Global IL-17 Monoclonal Antibody Injections Sales Volume (2021-2032)
  5. 1.2.3 Global IL-17 Monoclonal Antibody Injections Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 IL-17 Monoclonal Antibody Injections Market Dynamics
  1. 2.1 IL-17 Monoclonal Antibody Injections Industry Trends
  2. 2.2 IL-17 Monoclonal Antibody Injections Industry Drivers
  3. 2.3 IL-17 Monoclonal Antibody Injections Industry Opportunities and Challenges
  4. 2.4 IL-17 Monoclonal Antibody Injections Industry Restraints
3 IL-17 Monoclonal Antibody Injections Market by Company
  1. 3.1 Global IL-17 Monoclonal Antibody Injections Company Revenue Ranking in 2025
  2. 3.2 Global IL-17 Monoclonal Antibody Injections Revenue by Company (2021-2026)
  3. 3.3 Global IL-17 Monoclonal Antibody Injections Sales Volume by Company (2021-2026)
  4. 3.4 Global IL-17 Monoclonal Antibody Injections Average Price by Company (2021-2026)
  5. 3.5 Global IL-17 Monoclonal Antibody Injections Company Ranking (2024-2026)
  6. 3.6 Global IL-17 Monoclonal Antibody Injections Company Manufacturing Base and Headquarters
  7. 3.7 Global IL-17 Monoclonal Antibody Injections Company Product Type and Application
  8. 3.8 Global IL-17 Monoclonal Antibody Injections Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global IL-17 Monoclonal Antibody Injections Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 IL-17 Monoclonal Antibody Injections Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 IL-17 Monoclonal Antibody Injections Market by Type
  1. 4.1 IL-17 Monoclonal Antibody Injections Type Introduction
  2. 4.1.1 Human Origin
  3. 4.1.2 Rat Origin
  4. 4.1.3 Other
  5. 4.2 Global IL-17 Monoclonal Antibody Injections Sales Volume by Type
  6. 4.2.1 Global IL-17 Monoclonal Antibody Injections Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global IL-17 Monoclonal Antibody Injections Sales Volume by Type (2021-2032)
  8. 4.2.3 Global IL-17 Monoclonal Antibody Injections Sales Volume Share by Type (2021-2032)
  9. 4.3 Global IL-17 Monoclonal Antibody Injections Sales Value by Type
  10. 4.3.1 Global IL-17 Monoclonal Antibody Injections Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global IL-17 Monoclonal Antibody Injections Sales Value by Type (2021-2032)
  12. 4.3.3 Global IL-17 Monoclonal Antibody Injections Sales Value Share by Type (2021-2032)
5 IL-17 Monoclonal Antibody Injections Market by Application
  1. 5.1 IL-17 Monoclonal Antibody Injections Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global IL-17 Monoclonal Antibody Injections Sales Volume by Application
  6. 5.2.1 Global IL-17 Monoclonal Antibody Injections Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global IL-17 Monoclonal Antibody Injections Sales Volume by Application (2021-2032)
  8. 5.2.3 Global IL-17 Monoclonal Antibody Injections Sales Volume Share by Application (2021-2032)
  9. 5.3 Global IL-17 Monoclonal Antibody Injections Sales Value by Application
  10. 5.3.1 Global IL-17 Monoclonal Antibody Injections Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global IL-17 Monoclonal Antibody Injections Sales Value by Application (2021-2032)
  12. 5.3.3 Global IL-17 Monoclonal Antibody Injections Sales Value Share by Application (2021-2032)
6 IL-17 Monoclonal Antibody Injections Regional Sales and Value Analysis
  1. 6.1 Global IL-17 Monoclonal Antibody Injections Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global IL-17 Monoclonal Antibody Injections Sales by Region (2021-2032)
  3. 6.2.1 Global IL-17 Monoclonal Antibody Injections Sales by Region: 2021-2026
  4. 6.2.2 Global IL-17 Monoclonal Antibody Injections Sales by Region (2027-2032)
  5. 6.3 Global IL-17 Monoclonal Antibody Injections Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global IL-17 Monoclonal Antibody Injections Sales Value by Region (2021-2032)
  7. 6.4.1 Global IL-17 Monoclonal Antibody Injections Sales Value by Region: 2021-2026
  8. 6.4.2 Global IL-17 Monoclonal Antibody Injections Sales Value by Region (2027-2032)
  9. 6.5 Global IL-17 Monoclonal Antibody Injections Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America IL-17 Monoclonal Antibody Injections Sales Value (2021-2032)
  12. 6.6.2 North America IL-17 Monoclonal Antibody Injections Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe IL-17 Monoclonal Antibody Injections Sales Value (2021-2032)
  15. 6.7.2 Europe IL-17 Monoclonal Antibody Injections Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific IL-17 Monoclonal Antibody Injections Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific IL-17 Monoclonal Antibody Injections Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America IL-17 Monoclonal Antibody Injections Sales Value (2021-2032)
  21. 6.9.2 South America IL-17 Monoclonal Antibody Injections Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa IL-17 Monoclonal Antibody Injections Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa IL-17 Monoclonal Antibody Injections Sales Value Share by Country, 2025 VS 2032
7 IL-17 Monoclonal Antibody Injections Country-level Sales and Value Analysis
  1. 7.1 Global IL-17 Monoclonal Antibody Injections Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global IL-17 Monoclonal Antibody Injections Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global IL-17 Monoclonal Antibody Injections Sales by Country (2021-2032)
  4. 7.3.1 Global IL-17 Monoclonal Antibody Injections Sales by Country (2021-2026)
  5. 7.3.2 Global IL-17 Monoclonal Antibody Injections Sales by Country (2027-2032)
  6. 7.4 Global IL-17 Monoclonal Antibody Injections Sales Value by Country (2021-2032)
  7. 7.4.1 Global IL-17 Monoclonal Antibody Injections Sales Value by Country (2021-2026)
  8. 7.4.2 Global IL-17 Monoclonal Antibody Injections Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt IL-17 Monoclonal Antibody Injections Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt IL-17 Monoclonal Antibody Injections Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt IL-17 Monoclonal Antibody Injections Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis IL-17 Monoclonal Antibody Injections Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis IL-17 Monoclonal Antibody Injections Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Eli Lilly and Co.
  8. 8.2.1 Eli Lilly and Co. Company Information
  9. 8.2.2 Eli Lilly and Co. Business Overview
  10. 8.2.3 Eli Lilly and Co. IL-17 Monoclonal Antibody Injections Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly and Co. IL-17 Monoclonal Antibody Injections Product Portfolio
  12. 8.2.5 Eli Lilly and Co. Recent Developments
  13. 8.3 UCB
  14. 8.3.1 UCB Company Information
  15. 8.3.2 UCB Business Overview
  16. 8.3.3 UCB IL-17 Monoclonal Antibody Injections Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 UCB IL-17 Monoclonal Antibody Injections Product Portfolio
  18. 8.3.5 UCB Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca IL-17 Monoclonal Antibody Injections Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca IL-17 Monoclonal Antibody Injections Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 IL-17 Monoclonal Antibody Injections Value Chain Analysis
  2. 9.1.1 IL-17 Monoclonal Antibody Injections Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 IL-17 Monoclonal Antibody Injections Sales Mode & Process
  6. 9.2 IL-17 Monoclonal Antibody Injections Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 IL-17 Monoclonal Antibody Injections Distributors
  9. 9.2.3 IL-17 Monoclonal Antibody Injections Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst